Shire eyes blockbuster sales with 'best-in-class' HAE drug Takhzyro

24th August 2018 Uncategorised 0

Shire’s got a brand-new approval on its hands that could help it dominate the hereditary angioedema market for years to come—and rack up blockbuster sales in the process.

More: Shire eyes blockbuster sales with 'best-in-class' HAE drug Takhzyro
Source: fierce